title: Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas.
abstract: The role of gallbladder adenomas in the pathogenesis of gallbladder carcinoma is still controversial. Comparison of the genetic abnormalities seen in adenomas may provide insight into the potential role of gallbladder adenomas as precursor lesions to gallbladder carcinoma. The purpose of this study was to evaluate gallbladder carcinomas, gallbladder adenomas, and high-grade dysplastic lesions for the BRAF and the KRAS mutations and the mismatch repair protein abnormalities. We analyzed 29 gallbladder carcinomas (9 papillary and 20 nonpapillary adenocarcinomas), 16 adenomas (6 pyloric, 3 intestinal, 3 biliary, 3 mixed pyloric-biliary, and 1 mixed pyloric-intestinal), and 5 cases of high-grade dysplasia for activating missense mutations in KRAS codons 12 and 13 and BRAF V600E mutations. Mismatch repair protein immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 was also carried out. KRAS mutations were infrequently identified in gallbladder carcinoma (2/29, 7%) and high-grade dysplastic lesions (0/5, 0%). Compared with gallbladder carcinoma and high-grade dysplastic lesions, gallbladder adenomas frequently showed KRAS codon 12 mutations (5/16, 31%) (P=0.02). Adenomas with pyloric-type histology harbored KRAS mutations more often (4/10, 40%) than other histologic subtypes (1/6, 17%). Adenomas rarely showed BRAF mutations (1/16, 6%), and no cases of gallbladder carcinoma or high-grade dysplasia were positive for BRAF mutations. Both the adenomas and the carcinomas displayed intact expression of mismatch repair proteins by immunohistochemistry. The presence of frequent mutations in the RAS/RAF/MAPK pathway in the gallbladder adenomas compared with the gallbladder carcinomas suggest that the adenomas and the gallbladder carcinomas arise through distinctly different molecular pathways.
authors.affiliation: Department of Pathology, Washington University, St Louis, MO †Department of Pathology, Stanford University, Stanford, CA 94305, USA.
authors.forename: Rish K
authors.initials: RK
authors.lastname: Pai
authors.forename: Kaveh
authors.initials: K
authors.lastname: Mojtahed
authors.forename: Reetesh K
authors.initials: RK
authors.lastname: Pai
mesh_terms: D000230:Adenocarcinoma / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D000236:Adenoma / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D000368:Aged; D053843:DNA Mismatch Repair; D005260:Female; D005706:Gallbladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008297:Male; D008875:Middle Aged; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000378:metabolism; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000032:analysis* / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000032:analysis* / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D012189:Retrospective Studies; D015398:Signal Transduction / Q000235:genetics*; D014481:United States; D018631:ras Proteins / Q000032:analysis* / Q000235:genetics / Q000378:metabolism
chemical_list: C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020928:Mitogen-Activated Protein Kinases; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins